slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,578
Current window 93,661-93,690
Pages 3,953
Rows per page 30
Component
93,661-93,690 of 118,578
19
Clinical trial data for BA3011 in NSCLC patients.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
21
The slide serves as a section divider for a deep dive into a specific therapeutic platform.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
24
The slide uses a 2x2 grid of metrics to frame the market problem, followed by specific target population and success threshold data.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
26
SCCHN = Squamous Cell Carcinoma of the Head and Neck. ROR2 is the target biomarker.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
27
The slide uses a table to present clinical outcomes for specific tumor types, emphasizing the first-in-class potential of the therapy.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
28
The slide uses a process-oriented layout to describe clinical trial phases.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
30
The slide uses a combination of a comparison table for clinical data and a dot plot for NHP toxicity data.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
32
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
01
BioNTech | Investor Presentation Deck | 28 slidesBioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations 1 hit
06
BioNTech | Investor Presentation Deck | 28 slidesBioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
07
The slide uses a semi-circular layout to represent the company's strategic pillars.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
11
The slide uses a structured layout to present four pillars of corporate social responsibility.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
27
The slide uses a column-based layout to categorize strategic initiatives, with a footer highlighting foundational enablers.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · The AskLoop · Golden Circle1 hit
28
This is a standard corporate contact/footer slide.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
01
BioNTech | Results Presentation Deck | 32 slidesBioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations 1 hit
03
This is a standard pharmaceutical regulatory disclosure slide.BioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations 1 hit
09
The slide uses a three-row layout to categorize updates into label expansion, distribution, and R&D progress.BioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations 1 hit
13
Data shows monovalent BA.1 and bivalent vaccines as 4th doses; includes LOD line and statistical superiority/non-inferiority notes.BioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
14
The slide uses a 3D protein structure visualization and a heatmap to show mutation differences between Omicron lineages.BioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
20
Includes bar chart of neoantigen counts, line chart of immune response over time, and Kaplan-Meier survival curve.BioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations 1 hit
21
The slide highlights the mechanism of action for bispecific antibodies and a monospecific HexaBody, emphasizing their role in T cell and NK cell activation.BioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations 1 hit
28
Includes footnotes detailing market definitions and data sources.BioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations 1 hit
01
Blue Apron | Results Presentation Deck | 25 slidesBlue Apron | Results Presentation Deck | 25 slides · Blue Apron
Conference presentation Investor relations 1 hit
04
Blue Apron | Results Presentation Deck | 25 slidesBlue Apron | Results Presentation Deck | 25 slides · Blue Apron
Conference presentation Investor relations 1 hit
20
The slide uses a split-chart layout to compare two key financial metrics over time.Blue Apron | Results Presentation Deck | 25 slides · Blue Apron
Conference presentation Investor relations Beat · Strategic Initiatives1 hit
01
BMO Capital Markets | Investment Banking Pitch Book | 12 slidesBMO Capital Markets | Investment Banking Pitch Book | 12 slides · BMO Capital Markets
Consulting deck Investment bank 1 hit
01
BMO Capital Markets | Investment Banking Pitch Book | 22 slidesBMO Capital Markets | Investment Banking Pitch Book | 22 slides · BMO Capital Markets
Consulting deck Investment bank Beat · Situation & Context1 hit
10
The table compares initial and revised proposal premiums/discounts against a range of future P/NAV multiples and resulting IRRs.BMO Capital Markets | Investment Banking Pitch Book | 22 slides · BMO Capital Markets
Consulting deck Investment bank Beat · Problem & ComplicationLoop · Logic Chain1 hit
13
MI 61-101 refers to Multilateral Instrument 61-101, a Canadian regulation regarding protection of minority security holders in special transactions.BMO Capital Markets | Investment Banking Pitch Book | 22 slides · BMO Capital Markets
Consulting deck Investment bank Beat · Evidence & ProofLoop · Benchmark Gap1 hit
01
BMO Capital Markets | Investment Banking Pitch Book | 6 slidesBMO Capital Markets | Investment Banking Pitch Book | 6 slides · BMO Capital Markets
Consulting deck Investment bank 1 hit